Assignee
PRELUDE CORP
US·3 granted patents·6 pending applications·7 citations·filing 2015–2025
Top patents by PatentIndex Score
9 records- 0194US11821900B2Method of selection for treatment of subjects at risk of invasive breast cancerPRELUDE CORP·Filed 2022·Granted Nov 21, 2023·3 cites·13 claims
- 0284US11543411B2DCIS recurrence and invasive breast cancerPRELUDE CORP·Filed 2015·Granted Jan 3, 2023·4 cites·24 claims
- 0384US2026072032A1Dcis recurrence and invasive breast cancerPRELUDE CORP·Filed 2025·Application pending·0 cites
- 0471US12487242B2DCIS recurrence and invasive breast cancerPRELUDE CORP·Filed 2022·Granted Dec 2, 2025·0 cites·28 claims
- 0564US2022187301A1Method of selection for treatment of subjects at risk of invasive breast cancerPRELUDE CORP·Filed 2019·Application pending·0 cites
- 0661US2025273346A1Identification and methods of treatment of breast cancerPRELUDE CORP·Filed 2023·Application pending·0 cites
- 0749US2022341936A1Pd-l1 as a predictive marker for therapy in cancerPRELUDE CORP·Filed 2022·Application pending·0 cites
- 0847US2023392209A1Methods for treating a subject with local invasive breast cancer based on pdgfrb levelsPRELUDE CORP·Filed 2021·Application pending·0 cites
- 0945US2023375549A1Pd-1 as a predictive marker for therapy in cancerPRELUDE CORP·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →